CG Oncology announces a public offering Investing.com

IRVINE, Calif., December 11, 2024 (GLOBE NEWSWIRE) — CG Oncology, Inc. (Nasdaq: CGON ), a late-stage clinical biopharmaceutical company focused on the development and commercialization of a potential bladder sparing therapeutic for patients suffering from bladder cancer, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission of value and stock exchange of the USA (SEC) in connection with with the proposed public offering of 7,300,000 shares of its common stock. In addition, an existing shareholder of CG Oncology intends to tender and sell 700,000 common shares of CG Oncology in the proposed offering. CG Oncology will not receive income from the sale of shares by the selling shareholder. Furthermore, CG Oncology intends to provide the underwriters with a 30-day option to purchase from CG Oncology up to an additional 1,200,000 shares of its common stock at the public offering price, less discounts and commissions. The price of the public offering has not yet been determined. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Morgan Stanley & Co (NOT:). LLC, Goldman Sachs & Co (NOT:). LLC, TD Coven and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. LifeSci Capital LLC is acting as lead manager for the offering.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. A copy of the registration statement can be accessed through the SEC’s website at www.sec.gov. These securities may not be sold, or offers to be accepted for purchase, before the registration statement becomes effective. The proposed offer will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the proposed offering may be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NI 10014, by telephone at (866) 718-1649, or by email at prospectus@morganstanlei.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NI 10282, by telephone at (866) 471-2526, or by email at prospectus-ni@ni.email.gs.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855) 495-9846 or by email at TD.ECM_Prospectus@tdsecurities.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at sindprospectus@stifel.com.

This press release will not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be illegal prior to registration or qualification under the laws of securities of any such state or jurisdiction.

About CG oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on the development and commercialization of a potential bladder-sparing therapeutic for patients with bladder cancer. CG Oncology envisions a world where patients with urological cancer can benefit from its innovative immunotherapies to live with dignity and have an improved quality of life.

Forward-looking statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as are believe, expect, can, plan , potential, will and similar expressions, and are based on the current beliefs and expectations of CG Oncology. These forward-looking statements include, but are not limited to, CG Oncology’s expectations regarding the consummation, timing and size of the offering, including the offering and sale of shares by the selling stockholder, the grant of an option to purchase additional shares to the underwriters, and the fulfillment of customary conditions of closure in view offers. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in such statements. Risks and uncertainties that could cause actual results to differ materially include risks and uncertainties related to market conditions, the satisfaction of customary closing conditions in connection with the offering and other risks and uncertainties described in CG Oncology’s Annual Report on Form 10-K for the year . ended December 31, 2023, CG Oncology’s Quarterly Report on Form 10-K for the quarter ended September 30, 2024, the preliminary prospectus relating to the offering and other filings CG Oncology files with the SEC. All forward-looking statements speak only as of the date of this press release and are based on information available to CG Oncology as of the date of this release, and CG Oncology undertakes no obligation and does not intend to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

The media
Sarah Connors
VP, communication and patient advocacy
(508) 654-2277
sarah.connors@cgoncologi.com

Investor relations
Chau Cheng
VP, Investor Relations
(949) 342-8939
chau.cheng@cgoncologi.com

Source: CG Oncology Inc.